The levels of soluble CD137 are increased in tuberculosis patients and associated with disease severity and prognosis
European Journal of Immunology · 2024-08 · 54 (8)
DOI: 10.1002/eji.202350796 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, online erschienen am 25.06.2024. Verfasst von Ling Yi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Central Laboratory, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Bei…. Hauptthemen laut MEDLINE: Tumor Necrosis Factor Receptor Superfamily, Member 9, Biomarkers, Tuberculosis, Pulmonary, Severity of Illness Index. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Public Health Experts Project.
Abstract (Originalsprache)
Tuberculosis (TB) was the leading cause of death from a single infectious agent before the coronavirus pandemic. Therefore, it is important to search for severity biomarkers and devise appropriate therapies. A total of 139 pulmonary TB (PTB) patients and 80 healthy controls (HCs) were recruited for plasma soluble CD137 (sCD137) detection through ELISA. Moreover, pleural effusion sCD137 levels were measured in 85 TB patients and 36 untreated lung cancer patients. The plasma cytokine levels in 64 patients with PTB and blood immune cell subpopulations in 68 patients with PTB were analysed via flow cytometry. Blood sCD137 levels were higher in PTB patients ( p = 0.012) and correlated with disease severity ( p = 0.0056). The level of sCD137 in tuberculous pleurisy effusion (TPE) was markedly higher than that in malignant pleurisy effusion ( p = 0.018). Several blood cytokines, such as IL‐6 ( p = 0.0147), IL‐8 ( p = 0.0477), IP‐10 ( p ≤ 0.0001) and MCP‐1 ( p = 0.0057), and some laboratory indices were significantly elevated in severe PTB (SE) patients, but the percentages of total lymphocytes ( p = 0.002) and cytotoxic T cells ( p = 0.036) were significantly lower in SE patients than in non‐SE patients. In addition, the sCD137 level was negatively correlated with the percentage of total lymphocytes ( p = 0.0008) and cytotoxic T cells ( p = 0.0021), and PTB patients with higher plasma sCD137 levels had significantly shorter survival times ( p = 0.0041). An increase in sCD137 is a potential biomarker for severe TB and indicates a poor prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Central Laboratory, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
- Department of Clinical Laboratory, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
- National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beiji…
Förderung
- Beijing Public Health Experts Project
Zitieren
APA
Yi, L., Yan, J., Wei, P., Long, S., Wang, X., Gu, M., Yang, B., Chen, Y., Ma, S., Wang, C., Zheng, M., Sun, Q., Shi, Y., & Wang, G. (2024). The levels of soluble CD137 are increased in tuberculosis patients and associated with disease severity and prognosis. European Journal of Immunology, 54(8). https://doi.org/10.1002/eji.202350796
Vancouver
Yi L, Yan J, Wei P, Long S, Wang X, Gu M, et al. The levels of soluble CD137 are increased in tuberculosis patients and associated with disease severity and prognosis. European Journal of Immunology. 2024;54(8). doi:10.1002/eji.202350796
BibTeX
@article{Yi2024,
author = {Yi, Ling and Yan, Jun and Wei, Panjian and Long, Sibo and Wang, Xiaojue and Gu, Meng and Yang, Bin and Chen, Yan and Ma, Shang and Wang, Chaohong and Zheng, Maike and Sun, Qing and Shi, Yiheng and Wang, Guirong},
title = {The levels of soluble CD137 are increased in tuberculosis patients and associated with disease severity and prognosis},
journal = {European Journal of Immunology},
year = {2024},
volume = {54},
number = {8},
doi = {10.1002/eji.202350796}
}
EUVIMED